Azelastine HCl - CAS 79307-93-0
Catalog number: B0084-098591
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H25Cl2N3O
Molecular Weight:
418.36
COA:
Inquire
Targets:
Histamine Receptor
Description:
Azelastine HCl is a potent, second-generation, selective, histamine antagonist. It inhibits histamine via competing with histamine for the H1 receptor.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-098591 1 g $199 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
histamine antagonist
Purity:
>98%
Synonyms:
ZELASTINE HYDROCHLORIDE; AC1Q1SYE; HYDROGEN AZELASTINE CHLORIDE; AKOS026749829; DR002552
MSDS:
Inquire
Application:
histamine antagonist
InChIKey:
YEJAJYAHJQIWNU-UHFFFAOYSA-N
InChI:
InChI=1S/C22H24ClN3O.ClH/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16;/h2-3,6-11,18H,4-5,12-15H2,1H3;1H
Canonical SMILES:
[H+].CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl.[Cl-]
1.Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.
Morganroth J1, Lyness WH, Perhach JL, Mather GG, Harr JE, Trager WF, Levy RH, Rosenberg A. J Clin Pharmacol. 1997 Nov;37(11):1065-72.
Azelastine, an antihistamine with additional pharmacologic properties, was evaluated for a possible influence on pharmacokinetic and electrocardiographic parameters due to its coadministration with CYP3A4 inhibitor ketoconazole (200 mg every 12 hrs). Twelve volunteers entered this three-period, open-label study. Electrocardiographic parameters (PR, QRS and QTc intervals and U-wave morphology) were monitored after 14 days of azelastine HCl (4.4 mg every 12 hrs), after 7 days of either azelastine/ketoconazole or azelastine/placebo, and after a 21-day washout period, which was then followed by a 7-day administration of ketoconazole alone. None of the treatments resulted in meaningful alterations of electrocardiographic variables. Pharmacokinetic parameters could not be estimated because ketoconazole metabolites interfered with azelastine assay procedures. In vitro tests with human liver microsomes were used to characterize azelastine's inhibition spectrum.
2.High performance liquid chromatographic determination of azelastine and desmethylazelastine in guinea pig plasma and lung tissue.
Langevin CN1, Pivonka J, Wichmann JK, Kucharczyk N, Sofia RD. Biomed Chromatogr. 1993 Jan-Feb;7(1):7-11.
Analytical methods have been developed for the simultaneous quantitation of azelastine (AZ) and desmethylazelastine (DAZ) in guinea pig plasma and lung tissue. The methods require a 1.00 mL plasma sample and a minimum 0.100 g lung sample. Both methods employ liquid/liquid organic extraction and back-extraction into dilute acid. Quantitation is performed by high performance liquid chromatography on a 2 x 250 mm 5 microns Hypersil CPS column using fluorescence detection. The linear quantitative ranges for AZ.HCl and DAZ.HBr in plasma are 0.156-160 ng/mL and 0.313-160 ng/mL, respectively. The linear quantitative ranges for AZ.HCl and DAZ.HBr in lung tissue are 0.039-20 micrograms/g for both.
3.Investigation on the efficacy and tolerance of azelastine (HCL) nasal spray versus ebastine tablets in patients with seasonal allergic rhinit
Conde Hernández J1, Palma Aguilar JL, Delgado Romero J. Allergol Immunopathol (Madr). 1995 Mar-Apr;23(2):51-7.
We compared the efficacy and tolerance of Azelastine nasal spray (0.14 mg in each nostril twice a day) versus Ebastine tablets (10 mg) as a single night dose in a Phase IV open, randomized, parallel-group clinical trial lasting 14 days, conducted with 63 patients diagnosed of seasonal allergic rhinitis. The symptoms assessed before and after the treatment period were: sneezing, nasal pruritus, rhinorrhea, nasal obstruction, conjunctival erythema, eye pruritus, eye watering, photophobia, pharyngeal pruritus and cough. Each symptom was rated by the patients according to a 4-point scale: absent: 0, mild: 1, moderate: 2, and severe: 3. The score required to be included in the study was 8 or above. In addition, the resistance of nasal fossae was assessed, before and after the treatment, by active anterior rhinomanometry, as well as the appearance of adverse events. Both drugs were equally effective both in the control of symptoms and in decreasing the airway resistance and no statistically significant differences were observed in the variables tested in both groups.
4.[The problem of recurrence of rhino-sinusal polyposis: pilot trial with locally administered azelastine HCL in the prevention of relapses].
Bussi M1, Carlevato MT, Majore L, Battaglio S, Napoli P, Cortesina G. Acta Otorhinolaryngol Ital. 1995 Apr;15(2):101-6.
Recurrent nasal polyposis is one of the most common unsolved problem in clinical rhinology. In the last few years a great number of histopathological, immunohistochemical and immunological studies on nasal polyps have been carried out by several Authors. Notwithstanding this, the aetiology of these formations still remains unknown. Many data suggest that the presence of polyps is the result of various inflammatory, allergic and pseudo-allergic processes which finally lead to the formation of the oedema constitutive of the polyp itself. In the present report a preliminary trial was carried out in order to evaluate the possibility of preventing recurrences by means of a locally administered anti-H1 receptors drug (Azelastine HCl). In the reported first phase of the study 10 allergic patients with bilateral polyposis were evaluated. Attention was given to the anti-edemigen activity of the drug, as well as to its influence on the local production of Secretory IgA, 7SIgA and albumines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Histamine Receptor Products


CAS 58-33-3 Promethazine hydrochloride

Promethazine hydrochloride
(CAS: 58-33-3)

Promethazine hydrochloride is first-generation antihistamine of the phenothiazine family used as an antiallergic, in pruritus, for motion sickness and sedation,...

CAS 5579-84-0 Betahistine dihydrochloride

Betahistine dihydrochloride
(CAS: 5579-84-0)

Betahistine is a histamine H3 receptors inhibitor with IC50 of 1.9 μM.

CAS 80012-43-7 Epinastine

Epinastine
(CAS: 80012-43-7)

Epinastine is a second-generation antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis. It is highly selective for ...

Irdabisant
(CAS: 1005402-19-6)

Irdabisant is a potent, selective histamine H3 receptor inverse agonist. It displayed potent antagonist and inverse agonist activities in [³⁵S]guanosine 5'-O-(γ...

SUVN-G3031 hydrochloride
(CAS: 1394808-20-8)

SUVN-G3031 is a Histamine H3 receptor antagonist originated by Suven Life Sciences. Blockade of Histamine H3 receptor can augment the pre-synaptic release of bo...

UR-PI376
(CAS: 1192559-94-6)

This active molecular is a imidazolylpropylguanidine type compound as a hH4R agonist (histamine H4 receptor agonist) showing negligible hH1R and hH2R activities...

CAS 1104-22-9 Meclizine 2HCl

Meclizine 2HCl
(CAS: 1104-22-9)

Meclizine is a histamine H1 receptor antagonist used to treat nausea and motion sickness, has anti-histamine, anti-muscarinic and anti-oxidative phosphorylation...

CAS 5638-76-6 Betahistine

Betahistine
(CAS: 5638-76-6)

Betahistine is a H1 receptor agonist, which serves as a vasodilator. It is used in Meniere disease and in vascular headaches but may exacerbate bronchial asthma...

CAS 73903-17-0 JNJ-10191584

JNJ-10191584
(CAS: 73903-17-0)

JNJ-10191584 is a selective histamine H4 receptor antagonist. It inhibits mast cell in vitro with IC50 value of 138nM. JNJ-10191584 has antiinflammatory and ana...

CAS 13073-96-6 Decloxizine hydrochloride

Decloxizine hydrochloride
(CAS: 13073-96-6)

The hydrochloride salt form of Decloxizine, a hydroxyzine analogue, is a histamine 1 receptor antagonist and often known as an impurity of Hydroxyzine.

CAS 202189-78-4 Bilastine

Bilastine
(CAS: 202189-78-4)

Bilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

CAS 59-33-6 Pyrilamine maleate salt

Pyrilamine maleate salt
(CAS: 59-33-6)

Pyrilamine maleate salt is a first generation antihistamine and binds with high affinity to G(q/11) protein. It is commonly utilized as a radioligand binding as...

CAS 58-73-1 Diphenhydramine

Diphenhydramine
(CAS: 58-73-1)

Diphenhydramine is a histamine H1 antagonist. t competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous hist...

CAS 118288-08-7 Lafutidine

Lafutidine
(CAS: 118288-08-7)

Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.

CAS 99291-25-5 Levodropropizine

Levodropropizine
(CAS: 99291-25-5)

Levodropropizine possess anti-allergic and inhibits histamine receptor, reduces cough by interfering with stimulus activation of peripheral endings of sensory n...

ABT 239 tartrate
(CAS: 460748-71-4)

ABT 239 tartrate is a potent and selective histamine H3 receptor antagonist or inverse agonist.

CAS 15686-51-8 Clemastine

Clemastine
(CAS: 15686-51-8)

Clemastine is a histamine H1 antagonist commonly used for the symptoms of allergic rhinitis, hay fever, and cold.

CAS 1039399-17-1 PF-03654746 Tosylate

PF-03654746 Tosylate
(CAS: 1039399-17-1)

PF-03654746 Tosylate is a histamine H3 receptor antagonist undergoing a clinical trial for attention-deficit hyperactivity disorder (ADHD) therapy.

MK-0249
(CAS: 1167574-41-5)

This active molecular is a potent histamine H3 inverse antagonist. Current antipsychotic treatments have little impact on the cognitive deficits associated with...

CAS 34580-13-7 Ketotifen

Ketotifen
(CAS: 34580-13-7)

Ketotifen is a cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators, used as self-medication for the temporary relief of ...

Chemical Structure

CAS 79307-93-0 Azelastine HCl

Quick Inquiry

Verification code

Featured Items